Table 3.

TEAEs leading to discontinuation in more than one patient.

AE preferred term, n (%)	RCT teduglutide group, n = 109	RCT/extension teduglutide group, n = 173	RCT placebo group, n = 59
Any TEAE leading to discontinuation	10 (9.2)	34 (19.7)	4 (6.8)
Abdominal pain	1 (0.9)	8 (4.6)	0
Gastrointestinal stoma complication†	0	3 (4.4)	0
Nausea	1 (0.9)	3 (1.7)	0
Vomiting	1 (0.9)	3 (1.7)	0
Abdominal distension	2 (1.8)	2 (1.2)	0
Asthenia	1 (0.9)	2 (1.2)	0
Constipation	2 (1.8)	2 (1.2)	0

RCT, randomized controlled trial; TEAE, treatment-emergent adverse event.

^†Percentages calculated based on number of patients with a stoma (n = 68 for the RCT/extension teduglutide group).